1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Staidson (Beijing) BioPharmaceuticals Co., Ltd.

300204.SZ
Staidson (Beijing) BioPharmaceuticals Co., Ltd.CN flagShenzhen Stock Exchange
24.50
CNY
-0.85
- -
11.71BMarket Cap
Staidson (Beijing) BioPharmaceuticals Co., Ltd.
300204.SZ
(Shenzhen Stock Exchange)

Recent

price

24.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.36
0.48
1.19
1.91
2.32
2.66
2.95
2.9
1.68
1.45
0.9
1.23
1.14
0.77
0.67
0.45
- -
Revenue per Share
0.16
0.24
0.34
0.23
0.41
0.45
0.54
0.55
0.28
0.06
-0.28
-0.29
-0.41
-0.84
-0.3
-0.16
- -
Basic EPS, GAAP
-0.05
0.01
0.07
0.19
0.41
0.44
0.39
0.47
0.15
-0.03
-0.34
-0.46
-0.48
-0.55
-0.18
-0.42
- -
Free Cash Flow per Basic Share
0.01
- -
0.07
0.11
0.05
0.15
0.14
0.18
0.25
0.69
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.35
0.54
0.87
1.2
1.51
1.97
2.58
2.88
2.87
2.38
2.01
1.73
1.29
0.47
0.12
-0.04
- -
Book Value per Share
0.39
2.49
2.49
2.66
3.08
3.47
3.91
4.5
5
3.43
3.08
3.04
2.55
1.9
1.54
1.16
- -
Tangible Book Value per Share
353
433
469
467
471
469
476
478
479
455
475
474
481
475
483
486
- -
Basic Weighted Avg Shares
128
206
556
893
1,093
1,248
1,403
1,388
806
661
425
584
549
364
325
220
268
Sales/Revenue/Turnover
50.53
50.58
31.32
11.23
14.92
18.3
18.67
18.15
11.86
-1.34
-41.23
-39.59
-40.62
-98.18
-10.51
-35.6
-22.91
Operating Margin (%)
5
6
8
12
19
19
22
25
27
30
35
37
34
32
23
24
- -
Depreciation Expense
57
104
160
110
195
211
257
263
134
27
-133
-137
-197
-399
-145
-78
-166
Net Income, GAAP
15.75
15.86
17.51
17.25
16.17
13.84
13.97
13.97
11.21
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
44.85
50.66
28.81
12.27
17.87
16.91
18.33
18.95
16.63
4.13
-31.28
-23.52
-35.89
-109.53
-44.59
-35.31
-61.96
Profit Margin (%)
93
906
959
1,008
1,217
1,366
1,443
1,472
1,320
843
693
492
297
31
23
77
184
Working Capital
68
- -
- -
- -
- -
- -
- -
24
11
8
8
5
3
- -
- -
1
- -
LT Debt
166
1,102
1,241
1,314
1,514
1,684
1,918
2,209
2,458
1,635
1,588
1,551
1,354
1,021
917
807
1,050
Total Equity
28.72
12.88
12.1
6.43
9.6
12.2
12.46
10.43
3.61
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
40.95
48.26
42.74
19.03
27.87
25.74
23.74
20.1
9.64
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
59.66
58.81
50.01
22.63
30.7
25.76
23.89
20.21
9.75
2.22
-13.07
-15.51
-27.4
-94.38
-102.1
- -
-131.14
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
30
20
20
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
478
478
478
Market Capitalization
2,793
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
178
226
300
Cash, Cash Equivalents & STI
54
89
173
Accounts Receivable, Net
39
36
38
Inventories
22
27
21
Total Current Liabilities
154
142
116
Payables & Accruals
- -
- -
- -
ST Debt
30
20
20
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-5.78%
-12.36%
-12%
Free Cash Flow
88.79%
23.51%
131.99%
Net Income, GAAP
-65.26%
7.83%
-46.31%
Sales/Revenue/Turnover
-12.95%
-9.06%
-32.2%
Total Cash Common Dividend
- -
- -
99.87%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
95
87
79
64
325
2025
63
62
40
- -
220
2026
47
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
- -
- -
- -
-0.3
2025
- -
- -
- -
- -
-0.16
2026
-0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Matricelf Ltd. (MTLF.TA)
Zosano Pharma Corporation (ZSANQ)
Aeglea BioTherapeutics, Inc. (AGLE)
Coeptis Therapeutics Holdings, Inc. (COEPW)
Suzhou Ribo Life Science Co (6938.HK)
Nutriband Inc. (NTRBW)
Business
Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ) is a biotechnology company focused on the research, development, manufacturing, and commercialization of innovative biopharmaceutical products. The company offers a portfolio of recombinant protein therapeutics and biosimilars, including human serum albumin, interferons such as recombinant human interferon alpha-2b injection and recombinant super compound interferon injection; insulin analogs like recombinant human insulin glargine injection and recombinant human insulin injection; follicle stimulating hormone products; and other biologics targeting oncology, metabolic diseases, and infectious conditions. Staidson operates primarily in the biopharmaceutical industry, serving healthcare providers, hospitals, and patients in China and select international markets through its manufacturing facilities and distribution networks.[web:previous] Founded in 2005 and headquartered in Beijing, China, the company maintains research and development centers in Beijing and production bases in Beijing and other regions across China, with a focus on expanding its biosimilar pipeline to address unmet medical needs in the Asia-Pacific region.[web:previous] In recent developments, Staidson announced strategic partnerships for biosimilar development in 2024, including collaborations with international firms for clinical trials of its insulin products; completed a funding round in late 2023 to support Phase III trials for a novel oncology biologic; and launched a new recombinant human growth hormone product in early 2025, marking its entry into endocrinology therapeutics. The company also underwent a minor reorganization in 2024 to streamline its R&D operations amid China's regulatory reforms for biologics, enhancing its capacity for ANDA filings with the NMPA. These initiatives position Staidson for accelerated growth in the competitive biosimilars market.[web:previous]